| 000 | 01509 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250517201820.0 | ||
| 264 | 0 | _c20190716 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a1432-0827 | ||
| 024 | 7 |
_a10.1007/s00223-018-0404-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHorne, Anne M | |
| 245 | 0 | 0 |
_aBone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. _h[electronic resource] |
| 260 |
_bCalcified tissue international _c07 2018 |
||
| 300 |
_a55-61 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Remodeling _xdrug effects |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 |
_aDenosumab _xadministration & dosage |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOsteoporosis, Postmenopausal _xdrug therapy |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aRisedronic Acid _xadministration & dosage |
| 650 | 0 | 4 |
_aZoledronic Acid _xadministration & dosage |
| 700 | 1 | _aMihov, Borislav | |
| 700 | 1 | _aReid, Ian R | |
| 773 | 0 |
_tCalcified tissue international _gvol. 103 _gno. 1 _gp. 55-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00223-018-0404-6 _zAvailable from publisher's website |
| 999 |
_c28088152 _d28088152 |
||